Moderna Inc. (MRNA)
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average
Moderna (MRNA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRNA crossed above the 20-day moving average, suggesting a short-term bullish trend.
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership
A major vaccine producer came under pressure following a report federal health regulators plan to tighten vaccine approval rules. Meanwhile, an agreement with the world's most valuable company bolstered a software firm whose products help customers design and test semiconductors.
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More
Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back. The S&P 500 and Nasdaq slid about 0.2%, while the Dow dropped 0.4%.
Moderna stock slides as FDA moves to tighten vaccine guidelines
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock fell sharply on the news that the Food and Drug Administration (FDA) plans to implement stricter approval requirements for vaccines. The announcement raised investor concerns about potential delays and increased scrutiny for the company's pipeline of new products.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Moderna, Inc. (MRNA) Analyst/Investor Day Transcript
Moderna, Inc. ( MRNA ) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Stéphane Bancel - CEO & Director Stephen Hoge - President Jerh Collins - Chief Technical Operations & Quality Officer James Mock - Chief Financial Officer Jacqueline Miller - Chief Medical Officer Darin Edwards Raffael Nachbagauer Christine Shaw Kyle Holen Michelle Brown Rose Loughlin - Executive Vice President of Research Lavina Talukdar - Senior VP & Head of Investor Relations Rituparna Das Jeff Savard Craig Kennedy Jamie Collins Suzanne Tracy Wenhao Liu Andrew Semmes Amanda Sorrento Nathan Sauveur John Ward Daniel Kulp Kristine McKinney Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Myles Minter - William Blair & Company L.L.C., Research Division Elizabeth Webster - Goldman Sachs Group, Inc., Research Division Lili Nsongo - Leerink Partners LLC, Research Division Alexandria Hammond - Wolfe Research, LLC Conversation Stéphane Bancel CEO & Director Good morning, good afternoon.
What Is Going On With Moderna Stock?
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over the last 5 days, leading to a current market capitalization of around $10 billion.
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported earnings per share (EPS) of 3 cents.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $0.03 per share a year ago.
